Latest Biosyent Inc (BIOYF) Headlines BioSyen
Post# of 8
Posted On: 03/09/2014 1:41:44 AM
Latest Biosyent Inc (BIOYF) Headlines
BioSyent Pharma Signs Exclusive Licence and Distribution Agreement for a New Gastrointestinal Health Product Already Approved by Health Canada-2014 Launch Planned
Marketwire - Tue Mar 04, 7:03AM CST
BioSyent Inc. (TSX VENTURE: RX) ("BioSyent") is pleased to announce that its subsidiary BioSyent Pharma Inc. has signed an exclusive Canadian Licence and Distribution Agreement with an existing European partner for a gastrointestinal health product that has already been approved by Health Canada.
Heavy Rains Threaten Household Food Security
by Tendayi Nyahuye and Farai Rugeje - All Africa Global Media - Fri Feb 14, 2:05AM CST
Heavy rains received this month have impacted negatively on the food security of households after destroying crops in most parts of the country. Floods have been experienced in low-lying areas like Chivi, Masvingo and Tsholotsho, but the worst hit is the Tokwe-Mukosi area where the water in the dam has risen to dangerous levels.
BioSyent Named to the 2014 TSX Venture Top 50(R) Ranking-Only TSX Venture Company to Be Recognized as a Top Performer for the Past 3 Consecutive Years
Marketwire - Thu Feb 13, 7:01AM CST
BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) announced today that it has again been named as one of the TSX Venture Top 50 companies.
North American Palladium Reports Positive Production Ramp Up Progress
Marketwire Canada - Wed Feb 12, 4:03PM CST
All figures are in Canadian dollars except where noted.
BioSyent Announces Appointment of New Director
Marketwire - Thu Jan 16, 7:02AM CST
The Board of Directors of BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) is pleased to announce the appointment of Stephen Wilton to the Company's Board.
BioSyent to Present at the LD Micro VI Investor Conference
Marketwire - Mon Dec 02, 7:02AM CST
BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) is pleased to announce that CEO Rene Goehrum will be making a presentation at the LD Micro VI Investor Conference at 9am (PT), December 4, 2013 at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Mr. Goehrum will provide an overview of the Company and its corporate activities.
BioSyent Releases Q3 and Nine Month Results-Nine Month Sales Increase 53% and Profit Before Tax Up 77%
Marketwire - Thu Nov 21, 5:01AM CST
BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) released today a summary of its financial results for the three months (Q3) and nine months ending September 30, 2013.
BioSyent Releases Q2 and Six Month Results: Six Month Sales Increase 57% and Profit Before Tax Up 68%
Marketwire - Thu Aug 22, 7:02AM CDT
BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) released today a summary of its second quarter (Q2) and first half (H1) 2013 financial results for the three and six months ending June 30, 2013.
BioSyent Pharma Launches New FeraMAX(R) Powder-Water Soluble Polysaccharide-Iron Complex Iron Supplement
Marketwire Canada - Thu Jun 06, 7:00AM CDT
BioSyent Inc. ("BioSyent")(TSX VENTURE:RX) today announced that its subsidiary BioSyent Pharma Inc. has commenced the Canadian launch of its unique new oral iron supplement - FeraMAX(R) Powder.
BioSyent Named to the PROFIT 500 Ranking of Canada's Fastest-Growing Companies with a 5 Year Revenue Growth Rate of 355%
Marketwire - Tue Jun 04, 7:03AM CDT
BioSyent Inc. (TSX VENTURE: RX) ("BioSyent") is pleased to announce that PROFIT Magazine has ranked BioSyent as one of Canada's Fastest-Growing Companies in the just released 2013 rankings. Published in the Summer issue of PROFIT Magazine and online at PROFITguide.com, the PROFIT 500 ranks Canadian businesses by their revenue growth over five years. Based upon a five year revenue (2007-2012) growth rate of 355%, BioSyent ranked #183 on the PROFIT 500 list.
BioSyent Pharma Submits Two New Drugs to Health Canada for Marketing Approval
Marketwire - Thu May 23, 7:02AM CDT
BioSyent Inc. (TSX VENTURE: RX) ("BioSyent") is pleased to announce that its subsidiary, BioSyent Pharma Inc., has submitted two new drug products to Health Canada seeking marketing approval.
BioSyent Releases First Quarter Results-Sales Increase 70%, Profit Before Tax Up 76%
Marketwire - Wed May 22, 7:02AM CDT
BioSyent Inc. (TSX VENTURE: RX) ("BioSyent") released today a summary of its First Quarter (Q1) 2013 financial results.
BioSyent Pharma Signs Exclusive Licence and Distribution Agreement for a New Gastrointestinal Health Product Already Approved by Health Canada-2014 Launch Planned
Marketwire - Tue Mar 04, 7:03AM CST
BioSyent Inc. (TSX VENTURE: RX) ("BioSyent") is pleased to announce that its subsidiary BioSyent Pharma Inc. has signed an exclusive Canadian Licence and Distribution Agreement with an existing European partner for a gastrointestinal health product that has already been approved by Health Canada.
Heavy Rains Threaten Household Food Security
by Tendayi Nyahuye and Farai Rugeje - All Africa Global Media - Fri Feb 14, 2:05AM CST
Heavy rains received this month have impacted negatively on the food security of households after destroying crops in most parts of the country. Floods have been experienced in low-lying areas like Chivi, Masvingo and Tsholotsho, but the worst hit is the Tokwe-Mukosi area where the water in the dam has risen to dangerous levels.
BioSyent Named to the 2014 TSX Venture Top 50(R) Ranking-Only TSX Venture Company to Be Recognized as a Top Performer for the Past 3 Consecutive Years
Marketwire - Thu Feb 13, 7:01AM CST
BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) announced today that it has again been named as one of the TSX Venture Top 50 companies.
North American Palladium Reports Positive Production Ramp Up Progress
Marketwire Canada - Wed Feb 12, 4:03PM CST
All figures are in Canadian dollars except where noted.
BioSyent Announces Appointment of New Director
Marketwire - Thu Jan 16, 7:02AM CST
The Board of Directors of BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) is pleased to announce the appointment of Stephen Wilton to the Company's Board.
BioSyent to Present at the LD Micro VI Investor Conference
Marketwire - Mon Dec 02, 7:02AM CST
BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) is pleased to announce that CEO Rene Goehrum will be making a presentation at the LD Micro VI Investor Conference at 9am (PT), December 4, 2013 at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Mr. Goehrum will provide an overview of the Company and its corporate activities.
BioSyent Releases Q3 and Nine Month Results-Nine Month Sales Increase 53% and Profit Before Tax Up 77%
Marketwire - Thu Nov 21, 5:01AM CST
BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) released today a summary of its financial results for the three months (Q3) and nine months ending September 30, 2013.
BioSyent Releases Q2 and Six Month Results: Six Month Sales Increase 57% and Profit Before Tax Up 68%
Marketwire - Thu Aug 22, 7:02AM CDT
BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) released today a summary of its second quarter (Q2) and first half (H1) 2013 financial results for the three and six months ending June 30, 2013.
BioSyent Pharma Launches New FeraMAX(R) Powder-Water Soluble Polysaccharide-Iron Complex Iron Supplement
Marketwire Canada - Thu Jun 06, 7:00AM CDT
BioSyent Inc. ("BioSyent")(TSX VENTURE:RX) today announced that its subsidiary BioSyent Pharma Inc. has commenced the Canadian launch of its unique new oral iron supplement - FeraMAX(R) Powder.
BioSyent Named to the PROFIT 500 Ranking of Canada's Fastest-Growing Companies with a 5 Year Revenue Growth Rate of 355%
Marketwire - Tue Jun 04, 7:03AM CDT
BioSyent Inc. (TSX VENTURE: RX) ("BioSyent") is pleased to announce that PROFIT Magazine has ranked BioSyent as one of Canada's Fastest-Growing Companies in the just released 2013 rankings. Published in the Summer issue of PROFIT Magazine and online at PROFITguide.com, the PROFIT 500 ranks Canadian businesses by their revenue growth over five years. Based upon a five year revenue (2007-2012) growth rate of 355%, BioSyent ranked #183 on the PROFIT 500 list.
BioSyent Pharma Submits Two New Drugs to Health Canada for Marketing Approval
Marketwire - Thu May 23, 7:02AM CDT
BioSyent Inc. (TSX VENTURE: RX) ("BioSyent") is pleased to announce that its subsidiary, BioSyent Pharma Inc., has submitted two new drug products to Health Canada seeking marketing approval.
BioSyent Releases First Quarter Results-Sales Increase 70%, Profit Before Tax Up 76%
Marketwire - Wed May 22, 7:02AM CDT
BioSyent Inc. (TSX VENTURE: RX) ("BioSyent") released today a summary of its First Quarter (Q1) 2013 financial results.
(0)
(0)